Petros Pharmaceuticals, Inc. Amortization of Intangible Assets
Petros Pharmaceuticals, Inc. (PTPI) reported Amortization of Intangible Assets of $2.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2024-12-31 was $654.77K, a 15.27% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2024-09-30 was $700.00K, a 12.50% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2024-06-30 was $700.00K, a 12.50% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2024-03-31 was $715.28K, a 13.22% decline year-over-year.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2024 was $2.80M, a 14.43% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2023 was $3.27M, a 41.44% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2022 was $5.59M, a 18.62% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2021 was $6.87M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $654.77K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.35M derived: sum of 2 quarters · filed 2025-03-31 | $2.05M derived: sum of 3 quarters · filed 2025-03-31 | $2.80M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $700.00K 10-Q · filed 2024-11-13 | $1.40M derived: sum of 2 quarters · filed 2024-11-13 | $2.15M 10-Q · filed 2024-11-13 | $2.89M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-06-30 | $700.00K 10-Q · filed 2024-08-14 | $1.43M 10-Q · filed 2024-08-14 | $2.19M derived: sum of 3 quarters · filed 2025-03-31 | $2.99M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-03-31 | $715.28K 10-Q · filed 2024-05-15 | $1.49M derived: sum of 2 quarters · filed 2025-03-31 | $2.29M derived: sum of 3 quarters · filed 2025-03-31 | $3.09M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2023-12-31 | $772.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.57M derived: sum of 2 quarters · filed 2025-03-31 | $2.37M derived: sum of 3 quarters · filed 2025-03-31 | $3.27M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $800.00K 10-Q · filed 2024-11-13 | $1.60M derived: sum of 2 quarters · filed 2024-11-13 | $2.50M 10-Q · filed 2024-11-13 | $2.47M 10-Q · filed 2023-11-15 | $3.34M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-14 | $1.60M 10-Q · filed 2024-08-14 | $1.65M 10-Q · filed 2023-08-14 | $2.54M derived: sum of 3 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $824.24K 10-Q · filed 2023-05-15 | $1.74M derived: sum of 2 quarters · filed 2024-04-01 | ||||
| 2022-12-31 | $913.72K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-01 | $5.59M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $4.67M 10-Q/A · filed 2022-11-15 | |||||
| 2021-12-31 | $6.87M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |